Physician profile
Meredith Webster
NPI 1215518469
$1,337.22
in general payments reported to CMS, 2019-2025
14 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $398 · 2023: $235 · 2024: $543 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $912 · Education: $26.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $912.21 |
| Education | $26.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $335.66 | 2023-2025 | Myfembree, Gemtesa |
| Medtronic, INC. | $156.95 | 2024-2025 | Interstim, Signia |
| Boston Scientific Corporation | $140.85 | 2022 | |
| Mayne Pharma Commercial LLC | $137.36 | 2022-2025 | |
| Abbvie INC. | $112.46 | 2024-2025 | |
| Convatec INC. | $103.60 | 2023-2024 | |
| Astellas Pharma US INC | $99.00 | 2022 | |
| Pfizer INC. | $76.43 | 2022-2023 | |
| Millicent US INC | $59.94 | 2024 | Intrarosa, Femring |
| Exeltis, USA INC. | $32.92 | 2024 | Slynd |
| Mylan Pharmaceuticals INC. | $22.38 | 2022 | |
| Myovant Sciences INC. | $21.16 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $20.46 | 2022 | |
| Evofem Biosciences, INC. | $18.05 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meredith Webster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.